Dimerix CEO explains company’s different drug combo R&D strategy

December 6, 2016 Christoph Graener

 

Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company’s unusual business model. They discuss Dimerix’s Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix’s pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix’s lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.


Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Kathy Harrison – CEO, Dimerix

 

Previous Article
Covance: Expedited drug development with a new programmatic model
Covance: Expedited drug development with a new programmatic model

Drug development is undergoing a major transformation in order to align with the new norma—replacing a tran...

Next Article
Finding the value of real-world evidence
Finding the value of real-world evidence

Real-world evidence isn’t about what happens in the clinic, but is just as important to your success. It’s ...